Menu ×

HEALTHCARE & PHARMACEUTICAL

Dermatophytosis Treatment Market Segmentation by Type (Rx, OTC, Type 3, and Type 4); by Drug Used (Imidazole, Econazole, Clotrimazole, Miconazole, Ketoconazole, Terbinafine, Clotrimazole, Corticosteroid, Terbinafine, Itraconazole, Griseofulvin, and Others); and by End User (Hospitals, Clinics, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

IN THE NEWS

  • April 2021- Galderma announced the publication of phase 2b trial results demonstrating the long-lasting and rapid benefits of nemolizumab.

  • December 2019- Moberg Pharma declared that MOB-015 met the primary and secondary endpoints in the North American Phase 3 study including patients suffering from moderate nail fungus.   

Global Dermatophytosis Treatment Market Highlights 2022 – 2030

The global dermatophytosis treatment market is estimated to garner a large amount of revenue by growing at a robust CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing population of people with weak immune systems, and rising incidences of sedentary lifestyle among people. Along with these, increasing geriatric population contributing to the high occurrence of dermatophytosis across the globe is also expected to significantly raise the demand for the treatment in the forthcoming years. According to the World Health Organization, between 2015 to 2050, the percentage of the world’s population aged 60 years and older will nearly double from 12 percent to 22 percent. In 2050, 80% of older people will be living in low- and middle-income countries.

Upsurge in the number of hospital-acquired diseases is also predicted to expand the market in the near future. Furthermore, escalating private investments for conducting research and development activities to develop novel treatment in developed nations, and rise in healthcare funding are assessed to offer profitable opportunities for market growth in the imminent time.

Dermatophytosis Treatment Market Graph

Get more information on this reportDownload Sample PDF

The market is segmented by drug used into imidazole, econazole, clotrimazole, miconazole, ketoconazole, terbinafine, clotrimazole, corticosteroid, terbinafine, itraconazole, griseofulvin, and others, out of which, the itraconazole segment is anticipated to hold the largest share in the global dermatophytosis treatment market. This can be accounted to the broad antifungal spectrum and excellent effectiveness of this drug against fungal infections. Apart from these, high usage of itraconazole capsules for treating infections of the toenails is also projected to drive the segment’s growth in the future. Additionally, on the basis of end user, the clinics segment is evaluated to grab the largest share during the forecast period owing to the growing preference of patients to get treated by medical professionals operating in a specialty clinic facility. 

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Dermatophytosis Treatment Market Regional Synopsis

On the basis of geographical analysis, the global dermatophytosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the increasing geriatric population, and significant improvements in the healthcare facility in the region. In addition, rise in disposable income and literacy levels is also projected to boost the region’s market growth in the coming years. In the ASEAN region, Singapore accounts for the highest disposable income of approximately USD 30 thousand as of 2021, whereas Malaysia’s disposable income is calculated to reach a value of close to USD 5 thousand. Moreover, the market in North America is anticipated to acquire the largest share during the forecast period ascribing to the availability of highly developed healthcare infrastructure, favorable reimbursement policies, and growing awareness about the benefits of early diagnosis of the disease.

Dermatophytosis Treatment Market Share Graph

Get more information on this reportDownload Sample PDF

The global dermatophytosis treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global dermatophytosis treatment market includes the following segments:

By Type

  • Rx
  • OTC
  • Type 3
  • Type 4

By Drug Used

  • Imidazole
  • Econazole
  • Clotrimazole
  • Miconazole
  • Ketoconazole
  • Terbinafine
  • Clotrimazole
  • Corticosteroid
  • Terbinafine
  • Itraconazole
  • Griseofulvin
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

Growth Drivers

  • Growing Population of People with Weak Immune Systems
  • Rising Incidences of Sedentary Lifestyle Among People

Challenges

  • Availability of Alternative Treatment Options

Top Featured Companies Dominating the Market

  • Galderma S.A.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Novartis AG
  • Pfizer, Inc.
  • Moberg Pharma AB
  • Janssen Global Services, LLC
  • Valeant Pharmaceuticals International Inc.
  • Anacor Pharmaceuticals, Inc.
  • NovaQuest Capital Management, L.L.C.
  • Novan, Inc
  • Valeant Pharmaceuticals International Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved